Giavarina D, Carta M. Determination of reference interval for PSP, an early marker for sepsis. *Biochem Med (Zagreb)*. 25:64–8.
2.
Masson S, Caironi P, Fanizza C, Thomae R, Bernasconi R, Noto A, et al. Circulating presepsin (soluble CD14 subtype) as a marker of host response in patients with severe sepsis or septic shock: data from the multicenter, randomized ALBIOS trial. *Intensive Care Med*. 41:12–20.
3.
Nagata T, Yasuda Y, Ando M, Abe T, Katsuno T, Kato S, et al. Clinical impact of kidney function on presepsin levels. *PLoS One*. 10:e0129159.
4.
Chenevier-Gobeaux C, Trabattoni E, Roelens M, Borderie D, Claessens YE. Presepsin (sCD14-ST) in emergency department: the need for adapted threshold values? *Clin Chim Acta*. 427:34–6.
5.
Kotera A, Sagishima K, Tashiro T, Niimori D, Kamohara H, Kinoshita Y. A validation of presepsin levels in kidney dysfunction patients: four case reports. *J Intensive Care*. 2(63).
6.
Honore PM, Jacobs R, Hendrickx I, Waele E, Gorp V, Spapen HD. Presepsin and sepsis-induced acute kidney injury treated with continuous renal replacement therapy.
7.
Nakamura Y, Ishikura H, Nishida T, Kawano Y, Yuge R, Ichiki R, et al. Usefulness of presepsin in diagnosis of sepsis in patients with or without acute kidney injury. *BMC Anesthesiology*. 14(88).
8.
Bellomo R, Ronco C, Kellum JA, Mehta RL, Palevsky P. Acute Dialysis Initiative workgroup. Acute renal failure definition, outcome measures, animal models, fluid therapy, and inflammation technology needs: the second international consensus conference of the acute dialysis quality initiative (ADQI) group. *Crit Care*. 8:R204-212.
9.
Claessens YE, Trabattoni E, Grabar S, Quinquis L, Sahakian G, Anselmo M, et al. Plasmatic presepsin (sCD14-ST) concentrations in acute pyelonephritis in adult patients. *Clin Chim Acta*. 464:182–8.
10.
Wu CC, Lan HM, Han ST, Chaou CH, Yeh CF, Liu SH, et al. Comparison of diagnostic accuracy in sepsis between presepsin, procalcitonin, and C-reactive protein: a systematic review and meta-analysis. *Ann Intensive Care*. 7(91).
11.
Liu Y, Hou JH, Li Q, Chen KJ, Wang SN, Wang JM. Biomarkers for diagnosis of sepsis in patients with SIRS: a systematic review and meta-analysis. *SpringerPlus*. 5(2091).
12.
Ulla M, Pizzolato E, Lucchiari M, Loiacono M, Soardo F, Forno D, et al. Diagnostic and prognostic value of presepsin in the management of sepsis in the emergency department: a multicenter prospective study. *Crit Care*. 17:R168.
13.
Zanoni I, Granucci F. Role of CD14 in host protection against infections and in metabolism regulation. *Front Cell Infect Microbiol*. 3(32).
14.
Zheng Z, Jiang L, Ye L, Gao Y, Tang L, Zhang M. The accuracy of PSP for the diagnosis of sepsis from SIRS: a systematic review and meta-analysis. *Ann Intensive Care*. 5(48).
15.
Jacobs L, Wong HR. Emerging infection and sepsis biomarkers: will they change current therapies? *Expert Rev Anti Infect Ther*. 14:929–41.
16.
Shozushima T, Takahashi G, Matsumoto N, Kojika M, Okamura Y, Endo S. Usefulness of presepsin (sCD14-ST) measurements as a marker for the diagnosis and severity of sepsis that satisfied diagnostic criteria of systemic inflammatory response syndrome. *J Infect Chemother*. 17:764–9.
17.
Volanakis JE. Human C-reactive protein: expression, structure, and function. *Mol Immunol*. 38:189–97.
18.
Okamura Y, Yokoi H. Development of a point-of-care assay system for measurement of presepsin (sCD14-ST. *Clin Chim Acta*. 412:2157–61.
19.
Chenevier-Gobeaux C, Bardet V, Poupet H, Poyart C, Borderie D, Claessens YE. Presepsin (sCD14-ST) secretion and kinetics by peripheral blood mononuclear cells and monocytic THP-1 cell line. *Ann Biol Clin (Paris)*. 74(1):93–7.
20.
Qi Z, Wei W, Zhang XC. Presepsin as a novel sepsis biomarker. *World J Emerg Med*. 5:16–9.
21.
Mussap M, Noto A, Fravega M, Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. *J Matern Fetal Neonatal Med*. 2:12–4.
22.
Zhang J, Hu ZD, Song J, Shao J. Diagnostic value of presepsin for sepsis. *Medicine (Baltimore)*. 94(47).
23.
Meuleman P, Steyaert S, Libbrecht L, Couvent S, Houtte F, Clinckspoor F, et al. Human hepatocytes secrete soluble CD14, a process not directly influenced by HBV and HCV infection. *Clin Chim Acta*. 366:156–62.
Citation
Copyright
This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.
The statements, opinions and data contained in the journal are solely those of the individual authors and contributors and not of the publisher and the editor(s). We stay neutral with regard to jurisdictional claims in published maps and institutional affiliations.
